Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11203)
All Articles published online
|
Publishing Process of This Article
|
Jun 14, 2015 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21(22): 6820-6834 [PMID: 26078558 DOI: 10.3748/wjg.v21.i22.6820] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i22/6820.htm |
| Number | Citing Articles |
| 1 |
Qian Li, Manish Dhyani, Joseph R Grajo, Claude Sirlin, Anthony E Samir. Current status of imaging in nonalcoholic fatty liver disease. World Journal of Hepatology 2018; 10(8): 530-542 doi: 10.4254/wjh.v10.i8.530
|
| 2 |
Eider Talavera-Urquijo, Sarai Rodríguez-Navarro, Marc Beisani, Maria Teresa Salcedo-Allende, Aisha Chakkur, Marc Arús-Avilés, Manel Cremades, Salvador Augustin, María Martell, José M. Balibrea. Morphofunctional Changes After Sleeve Gastrectomy and Very Low Calorie Diet in an Animal Model of Non-Alcoholic Fatty Liver Disease. Obesity Surgery 2018; 28(1): 142 doi: 10.1007/s11695-017-2805-4
|
| 3 |
Alex Benjamin, Rebecca Zubajlo, Kai Thomenius, Manish Dhyani, Kanakaraju Kaliannan, Anthony E. Samir, Brian W. Anthony. Non-invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) using ultrasound image echogenicity. 2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2017; : 2920 doi: 10.1109/EMBC.2017.8037468
|
| 4 |
Niki Katsiki, Athanasios D Giannoukas, Vasilios G Athyros, Dimitri P Mikhailidis. Lipid-lowering treatment in peripheral artery disease. Current Opinion in Pharmacology 2018; 39: 19 doi: 10.1016/j.coph.2018.01.003
|
| 5 |
Arthur Balestra Silveira Ayres, Carollyne Rodovalho Guerra Carneiro, Martinho Antonio Gestic, Murillo Pimentel Utrini, Felipe David Mendonça Chaim, Francisco Callejas-Neto, Elinton Adami Chaim, Everton Cazzo. Identification of Predictors of Non-alcoholic Steatohepatitis and Its Severity in Individuals Undergoing Bariatric Surgery. Obesity Surgery 2024; 34(2): 456 doi: 10.1007/s11695-023-06986-5
|
| 6 |
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Anastasia Skalkou, Ioanna Zografou, Vasilios G. Athyros. The potential role of statins in treating liver disease. Expert Review of Gastroenterology & Hepatology 2018; 12(4): 331 doi: 10.1080/17474124.2018.1439379
|
| 7 |
Adriana Sánchez-García, Amirhossein Sahebkar, Mario Simental-Mendía, Luis E. Simental-Mendía. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacological Research 2018; 135: 144 doi: 10.1016/j.phrs.2018.08.008
|
| 8 |
I. V. Logacheva, T. A. Ryazanova, V. R. Makarova, O. V. Surnina. Non-Alcoholic Fatty Liver Disease in Cardiac Patients with Overweight and Obesity. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2019; 28(6): 27 doi: 10.22416/1382-4376-2018-28-6-27-37
|
| 9 |
Niki Katsiki, Anca Pantea Stoian, Paschalis Steiropoulos, Nikolaos Papanas, Andra-Iulia Suceveanu, Dimitri P. Mikhailidis. Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview. Metabolites 2020; 10(11): 465 doi: 10.3390/metabo10110465
|
| 10 |
M. Papagianni, K. Tziomalos. Non‐alcoholic fatty liver disease: an emerging predictor of stroke risk, severity and outcome. European Journal of Neurology 2018; 25(4): 610 doi: 10.1111/ene.13584
|
| 11 |
Vasilios G. Athyros, Stergios A. Polyzos, Jiannis Kountouras, Niki Katsiki, Panagiotis Anagnostis, Michael Doumas, Christos S. Mantzoros. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Current Vascular Pharmacology 2020; 18(2): 172 doi: 10.2174/1570161117666190405164313
|
| 12 |
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis, Dimitri P. Mikhailidis. Statins and non-alcoholic steatohepatitis. Journal of Hepatology 2016; 64(1): 241 doi: 10.1016/j.jhep.2015.09.021
|
| 13 |
Shengjun Xiong, Pengbo Wang, Shizhang Yin, Wanshu Deng, Yuanhui Zhao, Wenhang Li, Zhao Li, Ying Zhou, Shasha Yu, Hongmei Yang, Xiaofan Guo, Yingxian Sun. The association between liver fibrosis scores and chronic kidney disease. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1046825
|
| 14 |
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016; 65(8): 1109 doi: 10.1016/j.metabol.2016.05.003
|
| 15 |
Niki Katsiki, Vasilios G. Athyros, Asterios Karagiannis. Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study. Curr Med Res Opin 2017;33:797-801. Current Medical Research and Opinion 2017; 33(12): 2261 doi: 10.1080/03007995.2017.1333955
|
| 16 |
Manorama Swain, Preetam Nath, Prasant Kumar Parida, Jimmy Narayan, Pradeep Kumar Padhi, Girish Kumar Pati, Ayaskanta Singh, Bijay Misra, Debasis Misra, Sanjib Kumar Kar, Manas Kumar Panigrahi, Chudamani Meher, Omprakash Agrawal, Niranjan Rout, Kaumudee Pattnaik, Pallavi Bhuyan, Pramila Kumari Mishra, Shivaram Prasad Singh. Biochemical Profile of Nonalcoholic Fatty Liver Disease Patients in Eastern India with Histopathological Correlation. Indian Journal of Clinical Biochemistry 2017; 32(3): 306 doi: 10.1007/s12291-016-0612-7
|
| 17 |
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?. American Journal of Physiology-Gastrointestinal and Liver Physiology 2017; 312(6): G681 doi: 10.1152/ajpgi.00101.2017
|
| 18 |
Liat Mlynarsky, Dalit Schlesinger, Roni Lotan, Muriel Webb, Zamir Halpern, Erwin Santo, Oren Shibolet, Shira Zelber-Sagi. Non-alcoholic fatty liver disease is not associated with a lower health perception. World Journal of Gastroenterology 2016; 22(17): 4362-4372 doi: 10.3748/wjg.v22.i17.4362
|
| 19 |
Derek M. Erion, Hyun-Jun Park, Hui-Young Lee. The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Reports 2016; 49(3): 139 doi: 10.5483/BMBRep.2016.49.3.268
|
| 20 |
Takashi Kato, Man Hagiyama, Yasutoshi Takashima, Azusa Yoneshige, Akihiko Ito. Cell adhesion molecule-1 shedding induces apoptosis of renal epithelial cells and exacerbates human nephropathies. American Journal of Physiology-Renal Physiology 2018; 314(3): F388 doi: 10.1152/ajprenal.00385.2017
|
| 21 |
Arrigo F. G. Cicero, Alessandro Colletti. An update on the safety of nutraceuticals and effects on lipid parameters. Expert Opinion on Drug Safety 2018; 17(3): 303 doi: 10.1080/14740338.2018.1429404
|
| 22 |
Niki Katsiki, Anca Pantea Stoian, Manfredi Rizzo. Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path!. Clínica e Investigación en Arteriosclerosis (English Edition) 2022; 34: 23 doi: 10.1016/j.artere.2022.07.002
|
| 23 |
Munehisa Bekki, Nobuhiro Tahara, Atsuko Tahara, Sachiyo Igata, Akihiro Honda, Yoichi Sugiyama, Tomohisa Nakamura, Jiahui Sun, Yuki Kumashiro, Takanori Matsui, Yoshihiro Fukumoto, Sho-ichi Yamagishi. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study. Current Vascular Pharmacology 2019; 17(4): 411 doi: 10.2174/1570161116666180515154555
|
| 24 |
Kalliopi Pafili, Efstratios Maltezos, Nikolaos Papanas. Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 2016; 12(11): 1367 doi: 10.1080/17425255.2016.1229302
|
| 25 |
Sevket Balta. Atherosclerosis and Non-Alcoholic Fatty Liver Disease. Angiology 2022; 73(8): 701 doi: 10.1177/00033197221091317
|
| 26 |
Omar Elshaarawy, Johannes Mueller, Sina Straub, Sebastian Mueller. Nicht-alkoholische Fettlebererkrankung. 2022; : 137 doi: 10.1007/978-3-662-62484-5_13
|
| 27 |
TI Ledovskaya, ME Statsenko, SV Turkina, TA Konyakhina, KS Yusupov, EE Gorbacheva. Cardiovascular comorbidity in patients with nonalcoholic fatty liver disease. Medicine of Extreme Situations 2021; (2021(4)) doi: 10.47183/mes.2021.045
|
| 28 |
Niki Katsiki, Francesco Purrello, Costas Tsioufis, Dimitri P. Mikhailidis. Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 2017; 18(12): 1243 doi: 10.1080/14656566.2017.1351946
|
| 29 |
Cristiane Villela-Nogueira, Nathalie Leite, Claudia Cardoso, Gil Salles. NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms?. International Journal of Molecular Sciences 2016; 17(4): 460 doi: 10.3390/ijms17040460
|
| 30 |
Giovanna Muscogiuri, Ludovica Verde, Cem Sulu, Niki Katsiki, Maria Hassapidou, Evelyn Frias-Toral, Gabriela Cucalón, Agnieszka Pazderska, Volkan Demirhan Yumuk, Annamaria Colao, Luigi Barrea. Mediterranean Diet and Obesity-related Disorders: What is the Evidence?. Current Obesity Reports 2022; 11(4): 287 doi: 10.1007/s13679-022-00481-1
|
| 31 |
Rosaria Vincenza Giglio, Angelo Maria Patti, Dragana Nikolic, Giovanni Li Volti, Khalid Al-Rasadi, Niki Katsiki, Dimitri P. Mikhailidis, Giuseppe Montalto, Ekaterina Ivanova, Alexander N. Orekhov, Manfredi Rizzo. The effect of bergamot on dyslipidemia. Phytomedicine 2016; 23(11): 1175 doi: 10.1016/j.phymed.2015.12.005
|
| 32 |
Niki Katsiki, Ele Ferrannini, Christos Mantzoros. New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. Metabolism 2020; 107: 154218 doi: 10.1016/j.metabol.2020.154218
|
| 33 |
Niki Katsiki, Anca Pantea Stoian, Manfredi Rizzo. Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path!. Clínica e Investigación en Arteriosclerosis 2022; 34: S24 doi: 10.1016/j.arteri.2021.10.001
|
| 34 |
Erenius Toppo, S. Sylvester Darvin, S. Esakkimuthu, A. Stalin, K. Balakrishna, K. Sivasankaran, P. Pandikumar, S. Ignacimuthu, N.A. Al-Dhabi. Antihyperlipidemic and hepatoprotective effects of Gardenin A in cellular and high fat diet fed rodent models. Chemico-Biological Interactions 2017; 269: 9 doi: 10.1016/j.cbi.2017.03.013
|
| 35 |
Niki Katsiki, Michael Doumas, Vasilios Athyros. Metabolic syndrome: joint diagnostic criteria and links with comorbidities. Hormones 2019; 18(1): 107 doi: 10.1007/s42000-018-0074-9
|
| 36 |
Kaveh Hajifathalian, Zaid Tafesh, Russell Rosenblatt, Sonal Kumar, Edwin A. Homan, Reem Z. Sharaiha, David E. Cohen, Robert S. Brown, Brett E. Fortune. Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2022; 56(2): 173 doi: 10.1097/MCG.0000000000001503
|
| 37 |
Kalliopi Pafili, Manfredi Rizzo, Nikolaos Papanas. New antihyperglycaemic agents and cardiovascular disease. Current Opinion in Cardiology 2018; 33(4): 444 doi: 10.1097/HCO.0000000000000524
|
| 38 |
Shabnam Radbakhsh, Niki Katsiki, Raul D. Santos, Dimitri P. Mikhailidis, Christos S. Mantzoros, Amirhossein Sahebkar. Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation. Metabolism 2022; 132: 155211 doi: 10.1016/j.metabol.2022.155211
|
| 39 |
Angelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, Manfredi Rizzo, Ali A. Rizvi. Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 2019; 12(2): 129 doi: 10.1080/17512433.2019.1567328
|
| 40 |
Pakkapon Rattanachaisit, Paweena Susantitaphong, Kessarin Thanapirom, Roongruedee Chaiteerakij, Piyawat Komolmit, Pisit Tangkijvanich, Sombat Treeprasertsuk. Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Asian Biomedicine 2018; 12(1): 3 doi: 10.1515/abm-2018-0026
|
| 41 |
Mohsen Mazidi, Niki Katsiki, Dimitri P. Mikhailidis, Maciej Banach. Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease. Journal of the American College of Nutrition 2019; 38(7): 633 doi: 10.1080/07315724.2018.1507011
|
| 42 |
Laura J. Brattain, Brian A. Telfer, Manish Dhyani, Joseph R. Grajo, Anthony E. Samir. Objective Liver Fibrosis Estimation from Shear Wave Elastography. 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2018; : 1 doi: 10.1109/EMBC.2018.8513011
|
| 43 |
Morgan Marcuccilli, Michel Chonchol. NAFLD and Chronic Kidney Disease. International Journal of Molecular Sciences 2016; 17(4): 562 doi: 10.3390/ijms17040562
|
| 44 |
Vasilios G. Athyros, Niki Katsiki, Michael Doumas. Lipid association of India (LAI) expert consensus statement: part 2, specific patient categories. Clinical Lipidology 2018; 13(1): 1 doi: 10.1080/17584299.2017.1411068
|
| 45 |
Niki Katsiki, Genovefa Kolovou, Pablo Perez-Martinez, Dimitri P. Mikhailidis. Dyslipidaemia in the elderly: to treat or not to treat?. Expert Review of Clinical Pharmacology 2018; 11(3): 259 doi: 10.1080/17512433.2018.1425138
|
| 46 |
Kívia de Andrade, Fabiana Moura, John dos Santos, Orlando de Araújo, Juliana de Farias Santos, Marília Goulart. Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine. International Journal of Molecular Sciences 2015; 16(12): 30269 doi: 10.3390/ijms161226225
|
| 47 |
Georgios A. Christou, Niki Katsiki, John Blundell, Gema Fruhbeck, Dimitrios N. Kiortsis. Semaglutide as a promising antiobesity drug. Obesity Reviews 2019; 20(6): 805 doi: 10.1111/obr.12839
|
| 48 |
Rajkumar Chinnadurai, James Ritchie, Darren Green, Philip A Kalra. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrology Dialysis Transplantation 2019; 34(3): 449 doi: 10.1093/ndt/gfx381
|
| 49 |
Tae Woo Jung, Hye Jin Yoo, Kyung Mook Choi. Implication of hepatokines in metabolic disorders and cardiovascular diseases. BBA Clinical 2016; 5: 108 doi: 10.1016/j.bbacli.2016.03.002
|
| 50 |
Frank Tacke. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opinion on Investigational Drugs 2018; 27(3): 301 doi: 10.1080/13543784.2018.1442436
|
| 51 |
Giuseppe Dattilo, Francesco Borgia, Claudio Guarneri, Matteo Casale, Roberto Bitto, Claudia Morabito, Salvatore Signorelli, Niki Katsiki, Serafinello P. Cannavò. Cardiovascular Risk in Psoriasis: Current State of the Art. Current Vascular Pharmacology 2018; 17(1): 85 doi: 10.2174/1570161115666171116163816
|
| 52 |
Evangelos Chartampilas. Imaging of nonalcoholic fatty liver disease and its clinical utility. Hormones 2018; 17(1): 69 doi: 10.1007/s42000-018-0012-x
|
| 53 |
I. V. Logacheva, T. A. Ryazanova, S. B. Ponomarev, V. R. Makarova. Multivariate prognosis of non-alcoholic fatty liver disease development in visceral obesity in patients with coronary artery disease and hypertension. Russian Journal of Cardiology 2021; 26(1): 4015 doi: 10.15829/1560-4071-2021-4015
|
| 54 |
Vasilios G. Athyros, Dimitri P. Mikhailidis. High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice. Journal of Diabetes and its Complications 2016; 30(1): 9 doi: 10.1016/j.jdiacomp.2015.07.012
|
| 55 |
Zoran Gluvic, Ratko Tomasevic, Ksenija Bojovic, Milan Obradovic, Esma R. Isenovic. Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approach—the institutional adaptation to existing Clinical Practice Guidelines. Emergency and Critical Care Medicine 2022; 2(1): 12 doi: 10.1097/EC9.0000000000000016
|
| 56 |
Simona Panunzi, Sabina Maltese, Ornella Verrastro, Luca Labbate, Andrea De Gaetano, Maurizio Pompili, Esmeralda Capristo, Stefan R. Bornstein, Geltrude Mingrone. Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis. Diabetes, Obesity and Metabolism 2021; 23(4): 980 doi: 10.1111/dom.14304
|
| 57 |
Hadi Emamat, Hossein Farhadnejad, Hossein Poustchi, Azita Hekmatdoost. Galactose intake is related to nonalcoholic fatty liver disease. Nutrition & Food Science 2019; 49(3): 359 doi: 10.1108/NFS-06-2018-0174
|
| 58 |
Niki Katsiki, Nikolaos Perakakis, Christos Mantzoros. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?. Metabolism 2019; 98: iii doi: 10.1016/j.metabol.2019.07.009
|
| 59 |
Simona Cernea, Avivit Cahn, Itamar Raz. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Review of Clinical Pharmacology 2017; 10(5): 535 doi: 10.1080/17512433.2017.1300059
|
| 60 |
Niki Katsiki, Dimitrios Tousoulis. Diabetes mellitus and comorbidities: A bad romance. Hellenic Journal of Cardiology 2020; 61(1): 23 doi: 10.1016/j.hjc.2020.02.009
|
| 61 |
Kalliopi Pafili, Efstratios Maltezos, Nikolaos Papanas. Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?. Expert Opinion on Pharmacotherapy 2018; 19(3): 185 doi: 10.1080/14656566.2017.1413346
|
| 62 |
Rebecca E. Zubajlo, Alex Benjamin, Joseph R. Grajo, Kanakaraju Kaliannan, Jing X. Kang, Atul K. Bhan, Kai E. Thomenius, Brian W. Anthony, Manish Dhyani, Anthony E. Samir. Experimental Validation of Longitudinal Speed of Sound Estimates in the Diagnosis of Hepatic Steatosis (Part II). Ultrasound in Medicine & Biology 2018; 44(12): 2749 doi: 10.1016/j.ultrasmedbio.2018.07.020
|
| 63 |
A. Yu. Timakova, Yu. P. Skirdenko, M. A. Livzan, T. S. Krolevets, N. A. Nikolaev, A. V. Nelidova. Cardiovascular comorbidity in non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology 2020; (10): 88 doi: 10.31146/1682-8658-ecg-182-10-88-95
|
| 64 |
T. D. Filippatos, K. Alexakis, V. Mavrikaki, D. P. Mikhailidis. Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, “Prediabetes,” Diabetes and Atherosclerosis. Digestive Diseases and Sciences 2022; 67(1): 26 doi: 10.1007/s10620-021-06824-7
|
| 65 |
Jie Han, Yong Wang, Zhongshang Yuan, Lu Liu, Meng Zhao, Qingbo Guan, Haiqing Zhang, Qiu Li, Jin Xu, Ling Gao, Jiajun Zhao, Xu Zhang. Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosis. Medicine 2019; 98(11): e14896 doi: 10.1097/MD.0000000000014896
|
| 66 |
Tomas Vita, David J. Murphy, Michael T. Osborne, Navkaranbir S. Bajaj, Abhishek Keraliya, Sophia Jacob, Angel Joel Diaz Martinez, Ariana Nodoushani, Paco Bravo, Jon Hainer, Courtney F. Bibbo, Michael L. Steigner, Viviany R. Taqueti, Hicham Skali, Ron Blankstein, Marcelo F. Di Carli, Sharmila Dorbala. Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT. Radiology 2019; 291(2): 330 doi: 10.1148/radiol.2019181793
|
| 67 |
Manuela Abbate, Catalina M. Mascaró, Sofía Montemayor, Miguel Casares, Cristina Gómez, Lucia Ugarriza, Silvia Tejada, Itziar Abete, Maria Angeles Zulet, Antoni Sureda, J. Alfredo Martínez, Josep A. Tur. Non-Alcoholic Fatty Liver Disease Is Associated with Kidney Glomerular Hyperfiltration in Adults with Metabolic Syndrome. Journal of Clinical Medicine 2021; 10(8): 1717 doi: 10.3390/jcm10081717
|
| 68 |
Jelena Stevanović, Jorge Beleza, Pedro Coxito, António Ascensão, José Magalhães. Physical exercise and liver “fitness”: Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease. Molecular Metabolism 2020; 32: 1 doi: 10.1016/j.molmet.2019.11.015
|
| 69 |
Mustafa Koplay, Mustafa Gok, Mesut Sivri. The association between coronary artery disease and nonalcoholic fatty liver disease and noninvasive imaging methods. Electronic Journal of General Medicine 2019; 16(6): em165 doi: 10.29333/ejgm/110689
|
| 70 |
Niki Katsiki, Vasilios G. Athyros, Dimitri P. Mikhailidis. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs. Journal of Diabetes and its Complications 2017; 31(3): 521 doi: 10.1016/j.jdiacomp.2016.12.006
|
| 71 |
Niki Katsiki, George Dimitriadis, Dimitri P. Mikhailidis. Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection?. Angiology 2019; 70(7): 581 doi: 10.1177/0003319719848204
|
| 72 |
Yu. M. Kazakov, Yu. I. Manusha, T. A. Trybrat, N. I. Chekalina, ’ S. V. Shut’. THE CLINICAL AND BIOCHEMICAL FEATURES OF LIVER’ FUNCTIONAL STATE IN PATIENTS WITH ISCHEMIC HEART DISEASE IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Bulletin of Problems Biology and Medicine 2019; 3(152): 118 doi: 10.29254/2077-4214-2019-3-152-118-121
|
| 73 |
A Systematic Review of NAFLD-Associated Extrahepatic Disorders in Youths. Journal of Clinical Medicine 2019; 8(6): 868 doi: 10.3390/jcm8060868
|
| 74 |
Genovefa D. Kolovou, Gerald F. Watts, Dimitri P. Mikhailidis, Pablo Pérez-Martínez, Samia Mora, Helen Bilianou, George Panotopoulos, Niki Katsiki, Teik C. Ooi, José Lopez-Miranda, Anne Tybjærg-Hansen, Nicholas Tentolouris, Børge G. Nordestgaard. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. Current Vascular Pharmacology 2019; 17(5): 498 doi: 10.2174/1570161117666190507110519
|
| 75 |
Theodora Griva, Chrysoula Boutari, Konstantinos Tziomalos, Michael Doumas, Asterios Karagiannis, Vasilios G. Athyros. Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?. The Open Hypertension Journal 2017; 9(1): 1 doi: 10.2174/1876526201709010001
|
| 76 |
Niki Katsiki, Dimitri P Mikhailidis, Maciej Banach. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacologica Sinica 2018; 39(7): 1176 doi: 10.1038/aps.2018.40
|
| 77 |
Arinc Ozturk, Ramin Mohammadi, Theodore T. Pierce, Sagar Kamarthi, Manish Dhyani, Joseph R. Grajo, Kathleen E. Corey, Raymond T. Chung, Atul K. Bhan, Jagpreet Chhatwal, Anthony E. Samir. Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease. Ultrasound in Medicine & Biology 2020; 46(4): 972 doi: 10.1016/j.ultrasmedbio.2019.12.020
|
| 78 |
Seyed Moayed Alavian, Hosein Zadi. The Relation Between Non-alcoholic Fatty Liver Disease and the Risk of Coronary Heart Disease. Multidisciplinary Cardiovascular Annals 2022; 13(1) doi: 10.5812/mca-121262
|
| 79 |
Niki Katsiki, Vasilios G Athyros. Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. Current Medical Research and Opinion 2019; 35(7): 1305 doi: 10.1080/03007995.2019.1589152
|
| 80 |
Niki Katsiki, Vasilios G. Athyros, Dimitri P. Mikhailidis. Cardiovascular effects of sodium–glucose cotransporter 2 inhibitors: multiple actions. Current Medical Research and Opinion 2016; 32(9): 1513 doi: 10.1080/03007995.2016.1201465
|
| 81 |
Lucia Pacifico, Enea Bonci, Gian Andreoli, Michele Di Martino, Alessia Gallozzi, Ester De Luca, Claudio Chiesa. The Impact of Nonalcoholic Fatty Liver Disease on Renal Function in Children with Overweight/Obesity. International Journal of Molecular Sciences 2016; 17(8): 1218 doi: 10.3390/ijms17081218
|
| 82 |
Emir Muzurović, Brigita Smolović, Snežana Vujošević, Milan Petakov. Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. Current Vascular Pharmacology 2021; 19(5): 582 doi: 10.2174/1570161118666201008162537
|
| 83 |
Yu-Tao Zhan, Hai-Ying Su, Wei An. Glycosyltransferases and non-alcoholic fatty liver disease. World Journal of Gastroenterology 2016; 22(8): 2483-2493 doi: 10.3748/wjg.v22.i8.2483
|
| 84 |
Helena Katchman, Shira Zelber‐Sagi, Roni Baruch, Galia Berman, Idit F. Schwartz, Doron Schwartz, Richard Nakache, Yaacov Goykhman, Polina Katz, Oren Shibolet, Moshe Shashar, Ayelet Grupper. Progression and new onset of nonalcoholic fatty liver disease in living kidney donors compared to healthy controls. Clinical Transplantation 2018; 32(5) doi: 10.1111/ctr.13240
|
| 85 |
Mayur Virarkar, Janio Szklaruk, Corey T. Jensen, Melissa W. Taggart, Priya Bhosale. What's New in Hepatic Steatosis. Seminars in Ultrasound, CT and MRI 2021; 42(4): 405 doi: 10.1053/j.sult.2021.03.001
|
| 86 |
Evelyn Nunes Goulart da Silva Pereira, Beatriz Peres de Araujo, Karine Lino Rodrigues, Raquel Rangel Silvares, Carolina Souza Machado Martins, Edgar Eduardo Ilaquita Flores, Caroline Fernandes-Santos, Anissa Daliry. Simvastatin Improves Microcirculatory Function in Nonalcoholic Fatty Liver Disease and Downregulates Oxidative and ALE-RAGE Stress. Nutrients 2022; 14(3): 716 doi: 10.3390/nu14030716
|
| 87 |
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. Metabolism 2019; 101: 154001 doi: 10.1016/j.metabol.2019.154001
|
| 88 |
Jake P. Mann, Paul Carter, Matthew J. Armstrong, Hesham K. Abdelaziz, Hardeep Uppal, Billal Patel, Suresh Chandran, Ranjit More, Philip N. Newsome, Rahul Potluri, Michael W. Greene. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors. PLOS ONE 2020; 15(10): e0241357 doi: 10.1371/journal.pone.0241357
|
| 89 |
Niki Katsiki, Christos Mantzoros. Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)/DASH (dysmetabolism associated steatohepatitis). Metabolism 2021; 114: 154333 doi: 10.1016/j.metabol.2020.154333
|
| 90 |
Daniel A Giles, Maria E Moreno-Fernandez, Traci E Stankiewicz, Simon Graspeuntner, Monica Cappelletti, David Wu, Rajib Mukherjee, Calvin C Chan, Matthew J Lawson, Jared Klarquist, Annika Sünderhauf, Samir Softic, C Ronald Kahn, Kerstin Stemmer, Yoichiro Iwakura, Bruce J Aronow, Rebekah Karns, Kris A Steinbrecher, Christopher L Karp, Rachel Sheridan, Shiva K Shanmukhappa, Damien Reynaud, David B Haslam, Christian Sina, Jan Rupp, Simon P Hogan, Senad Divanovic. Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. Nature Medicine 2017; 23(7): 829 doi: 10.1038/nm.4346
|
| 91 |
Mengzhen Dong, Shousheng Liu, Mengke Wang, Yifen Wang, Yongning Xin, Shiying Xuan. Relationship between AGT rs2493132 polymorphism and the risk of coronary artery disease in patients with NAFLD in the Chinese Han population. Journal of International Medical Research 2021; 49(7): 030006052110192 doi: 10.1177/03000605211019263
|
| 92 |
Lars H. Breimer, Dimitri P. Mikhailidis. Does bilirubin protect against developing diabetes mellitus?. Journal of Diabetes and its Complications 2016; 30(4): 728 doi: 10.1016/j.jdiacomp.2016.01.019
|
| 93 |
Yun Kyung Cho, Yu Mi Kang, Jee Hee Yoo, Jiwoo Lee, Seung Eun Lee, Dong Hyun Yang, Joon-Won Kang, Joong-Yeol Park, Chang Hee Jung, Hong-Kyu Kim, Woo Je Lee. The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-30465-y
|
| 94 |
Xin-yan Yu, Xiao-xiao Song, Yu-ling Tong, Ling-yan Wu, Zhen-ya Song. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China. Medicine 2020; 99(48): e23360 doi: 10.1097/MD.0000000000023360
|
| 95 |
Niki Katsiki, Dimitri P Mikhailidis, Maciej Banach. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opinion on Pharmacotherapy 2019; 20(16): 2007 doi: 10.1080/14656566.2019.1649394
|
| 96 |
Karolina Grąt, Michał Grąt, Olgierd Rowiński. Usefulness of Different Imaging Modalities in Evaluation of Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines 2020; 8(9): 298 doi: 10.3390/biomedicines8090298
|
| 97 |
Manca Povsic, On Yee Wong, Richard Perry, Juliana Bottomley. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). Advances in Therapy 2019; 36(7): 1574 doi: 10.1007/s12325-019-00960-3
|
| 98 |
Binayak Sinha, Debasis Datta, Samit Ghosal. Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes. JGH Open 2021; 5(2): 219 doi: 10.1002/jgh3.12473
|
| 99 |
Niki Katsiki, Dimitri P Mikhailidis. Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial. Journal of Diabetes and its Complications 2017; 31(1): 1 doi: 10.1016/j.jdiacomp.2016.09.005
|
| 100 |
Jonathan M. Hazlehurst, Conor Woods, Thomas Marjot, Jeremy F. Cobbold, Jeremy W. Tomlinson. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016; 65(8): 1096 doi: 10.1016/j.metabol.2016.01.001
|
| 101 |
Arrigo F G Cicero, Alessandro Colletti, Gani Bajraktari, Olivier Descamps, Dragan M Djuric, Marat Ezhov, Zlatko Fras, Niki Katsiki, Michel Langlois, Gustavs Latkovskis, Demosthenes B Panagiotakos, Gyorgy Paragh, Dimitri P Mikhailidis, Olena Mitchenko, Bernhard Paulweber, Daniel Pella, Christos Pitsavos, Željko Reiner, Kausik K Ray, Manfredi Rizzo, Amirhossein Sahebkar, Maria-Corina Serban, Laurence S Sperling, Peter P Toth, Dragos Vinereanu, Michal Vrablík, Nathan D Wong, Maciej Banach. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutrition Reviews 2017; 75(9): 731 doi: 10.1093/nutrit/nux047
|
| 102 |
Niki Katsiki, Panagiotis Anagnostis, Kalliopi Kotsa, Dimitrios G. Goulis, Dimitri P. Mikhailidis. Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus. Current Pharmaceutical Design 2019; 25(18): 2051 doi: 10.2174/1381612825666190708192134
|
| 103 |
Mohamad Kareem Marrache, Don C. Rockey. Statins for treatment of chronic liver disease. Current Opinion in Gastroenterology 2021; 37(3): 200 doi: 10.1097/MOG.0000000000000716
|